Real-world data of cardiotoxicity during long-term therapy with trastuzumab in human epidermal growth factor receptor-2-positive metastatic breast cancer
Introduction/Objective. This study aims to investigate the cardiotoxicity of long-term therapy with trastuzumab in patients with HER-2-positive metastatic breast cancer. Methods. A total of 48 patients with metastatic HER-2-positive breast cancer were analyzed. The patients received long-term trastu...
Main Authors: | Iljovska Marina, Lazareva Emilija, Smichkoska Snezhana, Klisarovska Violeta, Stojkovski Igor, Petkovska Gordana, Mitreski Nenad |
---|---|
Format: | Article |
Language: | English |
Published: |
Serbian Medical Society
2023-01-01
|
Series: | Srpski Arhiv za Celokupno Lekarstvo |
Subjects: | |
Online Access: | http://www.doiserbia.nb.rs/img/doi/0370-8179/2023/0370-81792200113I.pdf |
Similar Items
-
Trastuzumab resumption after extremely severe cardiotoxicity in metastatic breast cancer patient: a case report
by: Santino Minichillo, et al.
Published: (2017-11-01) -
Risks of trastuzumab‐related cardiotoxicity in breast cancer patients in Taiwan
by: Wei‐Ting Chang, et al.
Published: (2021-12-01) -
Antioxidant Protection against Trastuzumab Cardiotoxicity in Breast Cancer Therapy
by: Gabriel Méndez-Valdés, et al.
Published: (2023-02-01) -
Risk factors associated with trastuzumab-induced cardiotoxicity in patients with human epidermal growth factor receptor 2-positive breast cancer
by: Wesam Abdel-Razaq, et al.
Published: (2019-01-01) -
Effects of trastuzumab and trastuzumab emtansine on corrected QT interval and left ventricular ejection fraction in patients with metastatic (HER2+) breast cancer
by: Rea Levicki, et al.
Published: (2023-02-01)